Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Angeles Alvarez Secord et al.|The Lancet Oncology|2019Cited by 533
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019Deborah K. Armstrong, Anita M. Engh, Adam C. ElNaggar et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 332
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Ursula A. Matulonis et al.|Clinical Cancer Research|2019Cited by 90
EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cellsHoracio Cárdenas, Daniela Matei|Oncotarget|2016Cited by 90